#USA #New York #class action lawsuit #Pomerantz LLP #MoonLake Immunotherapeutics

Investor Alert: Legal Action Against MoonLake Immunotherapeutics

The recent downturn in MoonLake Immunotherapeutics' stock has raised significant concerns among investors. On October 28, 2025, the Pomerantz Law Firm announced that it has initiated a class action lawsuit against the biopharmaceutical company, which trades under the NASDAQ ticker MLTX. This action comes as a response to disappointing results released from the company's Phase 3 VELA trials, which evaluated sonelokimab for treating various conditions.

Background on the Class Action

Pomerantz LLP is calling upon investors who suffered losses on their investments in MoonLake during the class period to come forward. Interested individuals are directed to contact Danielle Peyton at 646-581-9980 or via email at [email protected] Those affected are urged to provide their mailing address, phone number, and details regarding the number of shares purchased in the stock.

The crux of the lawsuit revolves around the allegations of securities fraud and other unlawful business practices by MoonLake and certain officials. The company reported on September 28, 2025, that the VELA trials did not meet significant endpoints, sparking considerable sell-offs in its stock. Following the announcement, shares plummeted by approximately 89.93%, closing at just $6.24 the next day.

Investor Implications and Deadlines

As the case progresses, investors have until December 15, 2025, to request to be appointed as a Lead Plaintiff. This designation would allow them to represent the interests of all class members in the litigation. The full text of the complaint can be accessed on Pomerantz's official website to provide additional context to those interested.

The swift and serious decline in MoonLake's stock post-announcement signals the potential widespread impact of the findings from the VELA trials and raises questions about the integrity of the company's communications leading up to the announcement.

About Pomerantz LLP

Founded by the influential Abraham L. Pomerantz, the firm has made its mark in corporate and securities litigation for over 85 years. Recognized as a leading organization in this field, Pomerantz has secured substantial awards for clients who have experienced losses due to corporate wrongdoing. Their extensive experience positions them to effectively advocate for victims of similar situations in the biotech sector.

Pomerantz offices span major cities, including New York, Chicago, London, and Tel Aviv, showcasing their global reach and commitment to investor rights.

Conclusion

The developments surrounding MoonLake Immunotherapeutics are a pivotal episode in investor protection and corporate ethics. Affected parties are encouraged to explore their options and consider joining the class action to seek recourse for their financial losses. For more information and to take action, interested investors should visit the Pomerantz Law Firm’s official page dedicated to this case.

For ongoing updates and to ensure compliance with all deadlines, keeping contact with legal representatives is crucial as the litigation unfolds.